North America Advanced Drug Delivery Systems Market Size (2024 - 2029)

North America Advanced Drug Delivery Systems Market Analysis

The North America Advanced Drug Delivery Systems Market size is estimated at USD 94.12 billion in 2024, and is expected to reach USD 105.21 billion by 2029, growing at a CAGR of 4.80% during the forecast period (2024-2029).

Advanced drug delivery system is an innovative technology that enables more effective, targeted, and controlled administration of pharmaceutical products, leading to improved therapeutic outcomes. In addition, advanced drug delivery results in increased bioavailability compared to traditional drug delivery systems.

Factors such as the development of new drugs and biologics, advancements in understanding human biology and diseases, and an increase in research and development spending are expected to boost the market’s growth over the forecast period. The increasing burden of chronic diseases requiring advanced drug formulation and enhanced therapeutic outcomes from novel drug delivery systems are further projected to boost market growth over the forecast period.

The increasing development of advanced drug delivery systems to improve bioavailability and overall treatment outcomes is likely to accelerate the market’s growth over the forecast period. For instance, according to an article published by Heliyon in June 2023, drug delivery systems were formulated with advanced technology and microcarrier technology to foster the systemic target delivery of the drug to improve treatment outcomes.

In addition, according to the same source, several new drug delivery approaches, including hyaluronic acid-based drug nanocarriers, drug delivery systems, and self-micro emulsifying drug-delivery systems, were developed to treat several solid tumors and pulmonary infections. Thus, such developments of advanced drug delivery systems to improve the therapeutic bioavailability of treatment are expected to increase the development of advanced drug delivery systems, boosting market growth over the forecast period.

Ongoing efforts to develop novel drug delivery systems for life-threatening conditions such as idiopathic pulmonary fibrosis (IPF) and others to facilitate effective drug delivery is another factor expected to spur market expansion. For instance, according to an article published by AAPS PharmSciTech in April 2024, treatment options for pulmonary fibrosis (IPF) are being formulated with advanced delivery systems such as chitosan nanoparticles, solid lipid nanocarriers, and liposomal-based nanocarriers for effective therapeutic administration of drugs. Thus, such incorporation of advanced drug delivery approaches in drug formulations is likely to increase their uptake, which is expected to boost market growth over the forecast period.

Moreover, companies are focusing on adopting various business strategies, such as new product launches, partnerships, and collaborations, that also contribute to market growth. For instance, in March 2024, HypoSpray Pharma and Nascent Biotech Inc. collaborated to manufacture an alternative delivery mechanism for patients to eliminate bi-weekly weekly infusions in cancer patients.

Similarly, in February 2022, NuGen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor, Shin-Ya Biotechnology Co. Ltd, for its InsuJet needleless injection system. This is part of a multi-year sales and distribution contract with a minimum commitment of CDN 100,000 (USD 73,326) during the first two years. Thus, such initiatives are further expected to fuel market growth over the coming years.

Therefore, owing to the aforementioned factors, such as the increasing advancements in biological drugs, growing R&D spending, and increasing company activities, the market is anticipated to grow over the forecast period. However, the product recalls of advanced drug delivery and the challenges in nanomedicine-based drug delivery are likely to impede market growth over the forecast period.

North America Advanced Drug Delivery Systems Industry Segmentation

As per the scope of the report, advanced drug delivery systems are improved methods for delivering the drug molecule to the targeted site in a more controlled manner. These methods improve the efficacy ratio of the currently available drugs. Delivering drugs at a controlled rate, slow and targeted delivery for onsite drug release and absorption is the basis for developing advanced drug delivery systems.

North America's advanced drug delivery systems market is segmented by type, application, technology, and geography. Based on type, the market is segmented into oral drug delivery system, injection-based drug delivery system, inhalation/pulmonary drug delivery system, transdermal drug delivery system, transmucosal drug delivery system, carrier-based drug delivery system, and other types. Based on application, the market is segmented into cardiovascular diseases, oncology, urology, diabetes, CNS, ophthalmology, inflammatory diseases, infections, and other applications. Based on technology, the market is segmented into prodrug, implants and intrauterine devices, targeted drug delivery, polymeric drug delivery, and other technologies. By geography, the market is segmented into the United States, Canada, and Mexico.